(Alliance News) - Syncona Ltd on Wednesday noted positive trial results for a portfolio company's gene therapy aimed at treating people with Gaucher's disease.

MeiraGTx (MGTX) announced the Company will exhibit five posters at the European Society of Gene and Cell Therapy, ESGCT, 2024 Annual Congress, ...

Gov. Kathy Hochul on Tuesday announced a $150 million investment in the new state-of-the-art therapy hub to be built on ...

The posters are available on the Posters and Publications page of the Company’s website.

Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces upcoming oral and poster ...

Editas Medicine is pushing its in vivo gene therapy strategy to the top of its agenda, boasting proof-of-concept data and ...

Clean Eatz, a health-focused lifestyle brand and meal plan franchise, wrapped Q3 with a celebration of its growth and brand achievements as well as individual franchisee excellence at its 2024 Clean ...

Solvd Inc., a global technology services and consulting company, today announced the appointment of Skylar Roebuck as its new ...

Nvelop Therapeutics, a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of ...

Coave's proprietary ALIGATER platform enables specific retargeting of AAV vectors to human receptors via a one-step chemical conjugation of peptide-based ligands at the surface of the capsid, ...

Vivet Therapeutics Presents Three Posters on Cerebrotendinous Xanthomatosis Program and Novel AAV Gene Delivery Platform at European Society of Gene and Cell Therapy Annual Congress 2024 ...

A top European court ruled against Harvard last week in a patent dispute against biotech company NanoString Technologies, ...